Trial
NCT02413853
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI); Prism Pharma Co., Ltd.
Condition
Colorectal Adenocarcinoma
Intervention
CBP/beta-catenin Antagonist PRI-724
Why stopped
Study drug supply issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-17